HAPPYMINI® IN THE HALLUX RIGIDUS

HAPPYMINI® IN THE HALLUX RIGIDUS   The ISIAT 2019 held in Lisbon in October was the occasion for LABRHA to present a study about HAppyMini® in the Hallux Rigidus (Osteoarthritis of the first metatarso-phalangeal joint). This prospective open-label multicentre pilot trial was conducted on 65 patients and safety was very good Read more…

HAPPYMINI® in the treatment of Temporo-Mandibular Osteoarthritis

  This prospective pilot study was conducted to show the Safety & Efficacy of a Single Injection of Mannitol-modified Cross-Linked Hyaluronic Acid (HAppyMini®) in the treatment of the Temporo-Mandibular Osteoartritis.   Results  at D180 : Treatment was efficient or very efficient for 94% of the patients Long lasting improvment of the inter-incisal distance  2/3 of patients reduced their painkillers Read more…

Safety and Predictive Factors of Short-Term Efficacy of a Single Injection of Mannitol-Modified Cross-Linked HA in Patients with Trapeziometacarpal OA.

    Like every year since 2012, LABRHA attended the EULAR Annual Meeting which took place in Amsterdam from the 13th  to the 16th of June 2018.      During the scientific session on “OSTEOARTHRITIS and microcrystalline disease”, Dr Thierry CONROZIER (France) presented results of the INSTINCT Study: influence of the radiological grade on the efficacy Read more…

Addition of a Polyol to HA: a Significant Advance in the Treatment of Osteoarthritis?

Is the addition of a polyol to hyaluronic acid a significant advance in the treatment of osteoarthritis? Conrozier T. Curr Rheumatol Rev. 2017 Jul 10. doi:10.2174/1573397113666170710115558. Viscosupplementation with intra-articular injections of hyaluronic acid is recommended as a second line treatment for knee OA, after failure of non-pharmacological modalities and usual Read more…